SEC Company Response from CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) (CIK 0001187953) (CELZ) — Dec 8, 2016
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) (CIK 0001187953)
Date: Dec. 8, 2016 · CIK: 0001187953 · Accession: 0001144204-16-138529
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-214741
Letter
Office of Healthcare and Insurance Division of Corporation Finance Re: Creative Medical Technology Holdings, Inc. Registration Statement on Form S-1 File No. 333-214741 Request for Effectiveness
Dear Ms. Hayes:
Pursuant to Rule 461 of Regulation C promulgated by the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended (the “Act”), Creative Medical Technology Holdings, Inc. (the “Company”) hereby requests that the registration statement of the Company on Form S-1 (Commission File No. 333-214741) be granted an effective date of Monday, December 12, 2016, 11:00 a.m. EST, or as soon thereafter as practicable. We request that we be notified of such effectiveness by a telephone call or email to our legal counsel, Ronald N. Vance, at (801) 446-8802, ron@vancelaw.us. The Company hereby authorizes Mr. Vance to orally modify or withdraw this request for acceleration.
This request for acceleration will acknowledge that the Company is aware of its obligations under the Act and the Securities Exchange Act of 1934, as amended, as they relate to the proposed public offering of the securities specified in the above registration statement. The Company further acknowledges that:
· should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
· the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
· the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Please direct any questions or comments regarding this acceleration request to Mr. Vance.
Sincerely,
/s/ Timothy Warbington
Show Raw Text
CORRESP
1
filename1.htm
Creative
Medical Technology Holdings, Inc.
2007 W Peoria Ave
Phoenix, AZ 85029
(602) 680-7439
timwarbington@yahoo.com
December 8, 2016
Suzanne Hayes
Assistant Director
Office of Healthcare and Insurance
Division of Corporation Finance
US Securities and Exchange Commission
Re: Creative Medical Technology Holdings, Inc.
Registration Statement on Form S-1
File No. 333-214741
Request for Effectiveness
Dear Ms. Hayes:
Pursuant to Rule 461 of Regulation C promulgated
by the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended (the
“Act”), Creative Medical Technology Holdings, Inc. (the “Company”) hereby requests that the
registration statement of the Company on Form S-1 (Commission File No. 333-214741) be granted an effective date of Monday, December
12, 2016, 11:00 a.m. EST, or as soon thereafter as practicable. We request that we be notified of such effectiveness by a telephone
call or email to our legal counsel, Ronald N. Vance, at (801) 446-8802, ron@vancelaw.us. The Company hereby authorizes Mr. Vance
to orally modify or withdraw this request for acceleration.
This request for acceleration will acknowledge
that the Company is aware of its obligations under the Act and the Securities Exchange Act of 1934, as amended, as they relate
to the proposed public offering of the securities specified in the above registration statement. The Company further acknowledges
that:
· should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose
the Commission from taking any action with respect to the filing;
· the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does
not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
· the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by
the Commission or any person under the federal securities laws of the United States.
Please direct any questions or comments
regarding this acceleration request to Mr. Vance.
Sincerely,
/s/ Timothy Warbington
Timothy Warbington, CEO
cc: Ronald N. Vance, Esq.
Mary Beth Breslin, SEC